Analyst Conference Call Summary

conference date: December 5, 2013 @ 8:00 AM Pacific Time
for quarter ending: October 30, 2013 (Q1, first quarter fiscal 2014)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was , % sequentially from $114.0 million

Net income was , % sequentially from $10.2 million

EPS (earnings per share) were , % sequentially from $0.25

Guidance:

No specific guidance (Cantel never has provided specific guidance).

Conference Highlights:

Realigning reporting segments were changed, adding some formerly "other" revenue to Water Purification/Mar Cor segment.

Endoscopy segment revenue was a record , sequentially from $44.5 million, and up % y/y.

Healthcare Disposables (Crosstex and SPS) sales were up

Water Purification and Filtration segment (Mar Cor) revenue was $ million, %sequential.y from $35.7 million, and up % y/y.

Therapeutic Filtration (formerly Dialysis) segment sales % y/y.

% gross margin, sequentially from 43.1%

Cash and equivalents balance ended at , sequentially from $34.1 million. Debt ended at $ million. Cash flow from operations $ million. Cap ex $ million.

EBITDAS was $, sequentially from $21.6 million and up from $ million year-earlier.

Cost of sales was $ million, leaving gross profit of $ million. Operating expenses were $ million consisting of: $ million selling; $ million general and administrative; $ million research and development. Interest expense $ million. Income taxes $ million.

Q&A:

OpenIcon Analyst Conference Summaries Main Page

CantelMedical.com

Search

More Analyst Conference Pages: